Applied DNA Sciences 13G Filing Shows S.H.N. Financial Investments Ltd. Reported A 9.99% Stake In The Co As Of May 28, 2024
$APDN
Other Consumer Services
Consumer Discretionary
- SEC Filing
- SEC Filing
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2022 | $8.00 → $6.00 | Buy | HC Wainwright & Co. |
| 8/13/2021 | $13.00 → $11.00 | Buy | HC Wainwright & Co. |
STONY BROOK, NY / ACCESSWIRE / October 30, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a registered direct offering and concurrent private placement with gross proceeds to the Company expected to be approximately $6.5 million before deducting placement agent fees and other estimated expenses payable by the Company.The offering is comprised of 20,312,500 shares (the "Shares") of the Company's common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.32 per share of common stock (or pre-funded warrants in lieu thereof, which shall have the same purchase price, less
STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit. Maxim Group LLC is presenting the virtual summit from October 15th to 17th.Jason McCarthy, Ph.D., Maxim's senior managing director and head of Biotechnology Research, will interview Dr. Hayward.Applied DNA's fireside chat will be available for viewing by registered conference attendees on Wednesday, October 16, 2024.Details for the fireside chat are as follows:Date: Wednesday, October 1
STONY BROOK, NY / ACCESSWIRE / September 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on September 17, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").As previously reported, the Company was notified on July 12, 2024, that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as re
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $6.00 from $8.00 previously
HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $11.00 from $13.00 previously
HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $13.00 from $14.00 previously
Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciencesSTONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. Dr. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the Company's three business segments, incl
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development. In this newly created role, Mr. Shorrock will lead Applied DNA’s legal, regulatory, IP, and business development functions. Dr. James A. Hayward, president and CEO, Applied DNA, said, “As we continue to advance the adoption of our PCR-based, LinearDNATM manufacturing platform across highly regulated markets and further devel
- Reuters
S-1 - APPLIED DNA SCIENCES INC (0000744452) (Filer)
PRE 14A - APPLIED DNA SCIENCES INC (0000744452) (Filer)
8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)
SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)
STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter
STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. The Company will not host a financial webcast or call for this most recent quarterly reporting period. The Company will host an investor update call on June 12, 2024.Summary Second Quarter Fiscal 2024 Financial Results:Total revenues were approximately $930 thousand for the three-month period March 31, 2024, compared to $4.4 million for the second quarter
STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2024 financial results after market close on Thursday, February 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, February 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-940